Quick Answer
BridgeBio Pharma, Inc. reported Total Revenue of $502.08 million for fiscal year 2025.
BridgeBio Pharma, Inc. Total Revenue — Annual History
| Fiscal Year | Total Revenue | YoY Change |
|---|---|---|
| 2025 | $502.08M | +126.3% |
| 2024 | $221.90M | +2285.3% |
| 2023 | $9.30M | -88.0% |
| 2022 | $77.65M | +11.4% |
| 2021 | $69.72M | +745.1% |
| 2020 | $8.25M | -79.7% |
| 2019 | $40.56M | — |
Quarterly Total Revenue
| Quarter Ending | Total Revenue | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $120.70M | +4318.0% | +9.2% |
| June 30, 2025 | $110.56M | +4999.9% | -5.2% |
| March 31, 2025 | $116.63M | -44.8% | +4169.1% |
| September 30, 2024 | $2.73M | -33.2% | +26.0% |
| June 30, 2024 | $2.17M | +32.1% | -99.0% |
| March 31, 2024 | $211.12M | +11461.9% | +5060.6% |
| September 30, 2023 | $4.09M | +1110.4% | +149.3% |
| June 30, 2023 | $1.64M | -97.8% | -10.1% |
- BridgeBio Pharma, Inc. showed an increase of +126.3% in Total Revenue compared to the prior fiscal year.
- Over the 2019–2025 period, BridgeBio Pharma, Inc.’s total revenue has grown by 1137.9% (from $40.56 million to $502.08 million).
- The most recent figure is from BridgeBio Pharma, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on February 24, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: